Table 1 Seminal studies describing TNFi drug retention rates and TNFi dose reduction, tapering or discontinuation
Author | No. AS patients | TNFi drug retention rate |
Carmona et al. 2006 [5] | 657 | 1 year 88%, 2 years 82%, 3 years 76% |
Heiberg et al. 2008 [8] | 249 | 1 year 78% |
Pavelka et al. 2009 [7] | 310 | 1 year 84%, 2 years 76%, 3 years 72% |
Glintborg et al. 2010 [9] | 842 | 1 year 74%, 2 years 63% |
Kristensen et al. 2010 [16] | 243 | 2 years 74% |
Lie et al. 2011 [14] | 514 | 1 year 76%, 2 years 65% |
Arends et al. 2011 [12] | 220 | 1 year 71%, 2 years 66% |
Arends et al. 2012 [13] | 111 | 3 years 65% |
Glintborg et al. 2013 [11] | 1436 | 2 years 58% |
Heinonen et al. 2015 [15] | 543 | 1 year 84%, 2 years 75% |
Lorenzin et al. 2015 [17] | 70 | 1 year 77%, 2 years 70%, 3 years 57%, 4 years 53%, 5 years 50% |
Arends et al. 2017 [33] | 89 | 7 years 51% |
Author | No. AS patients | TNFi discontinuation or reduction |
Baraliakos et al. 2005 [31] | 42 | 91% relapse 36 weeks after infliximab discontinuation |
Brandt et al. 2005 [32] | 26 | > 2/3 relapse 12 weeks after etanercept discontinuation |
Zhao et al. 2018 [34] | 35 | 60% relapse 3 years after etanercept discontinuation |
Lee et al. 2010 [35] | 109 | Etanercept dose reduction may be possible |
De Stefano et al. 2014 [36] | 38 | Etanercept reduction may be possible at clinical remission |
Cantini et al. 2013 [37] | 78 | Etanercept reduction may be possible at clinical remission |
Yates et al. 2015 [38] | 89 | Etanercept dose reduction may be possible |
Zavada et al. 2016 [39] | 136 | TNFi reduction may be possible at low disease activity |
Park et al. 2016 [40] | 165 | TNFi reduction linked to more rapid radiographic progression |
Fong et al. 2016 [41] | 125 | TNFi reduction may be possible at low disease activity |